logo

For the Inventor, By the Inventor

Kobe, Japan

Mikio Kurokawa

This inventor holds 6 USPTO granted patents. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1976-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikio Kurokawa. Retrieved from https://idiyas.com/inventor/mikio-kurokawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 133(Granted Patents)


Location History:

  • Kobe, JA (1976)
  • Kobe, JP (1979 - 1992)

Company Filing History:

goldMedal6 out of 129 
 
Dainippon Pharmaceutical Company, Limited
 patents

Years Active: 1976-1992

Loading Chart...
6 patents (USPTO):Explore Patents
1. 5128354 - Agent for treating ischemic brain damage (1992-07-07),
2. 4889858 - Dibenz[b,e]oxepin derivatives and pharmaceutical composition containing (1989-12-26),
3. 4749703 - Calcium antagonist piperazine derivatives, and compositions therefor (1988-06-07),
4. 4356186 - Acetic acid derivatives and composition containing the same (1982-10-26),
5. 4172896 - Methane-sulfonamide derivatives, the preparation thereof and composition (1979-10-30),
6. 3948928 - 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid (1976-04-06),

Title: Mikio Kurokawa: Innovator in Pharmaceutical Science

Introduction

Mikio Kurokawa is a prominent inventor based in Kobe, Japan. He has made significant contributions to the field of pharmaceutical science, particularly in the treatment of ischemic brain damage. With a total of 6 patents to his name, Kurokawa's work has had a meaningful impact on medical research and development.

Latest Patents

One of Kurokawa's latest patents is an agent for treating ischemic brain damage, which involves dibenz[b,e]oxepin derivatives and a pharmaceutical composition containing these compounds. This innovative approach aims to provide new therapeutic options for patients suffering from brain injuries.

Career Highlights

Kurokawa is currently associated with Dainippon Pharmaceutical Company, Limited, where he continues to advance his research and development efforts. His work at this esteemed company has allowed him to explore new avenues in drug formulation and therapeutic applications.

Collaborations

Throughout his career, Kurokawa has collaborated with notable colleagues, including Hitoshi Uno and Yoshinobu Masuda. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Mikio Kurokawa's contributions to pharmaceutical science exemplify the spirit of innovation in the medical field. His dedication to developing effective treatments for ischemic brain damage showcases the importance of research and collaboration in advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…